FDA Determines Regulatory Review Period for SAVAYSA Patent Extension Application

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for SAVAYSA, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to a submission to the U.S. Patent and Trademark Office (USPTO) for patent extension.